Scientists study why opioid withdrawal hits some harder than others

NCT ID NCT05027919

Recruiting now Knowledge-focused Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how opioid withdrawal symptoms vary from person to person. Sixty adults with opioid use disorder will go through a medically supervised taper using hydromorphone and lofexidine. Researchers will measure withdrawal severity during the taper and after a naloxone challenge. The goal is to better understand individual differences in withdrawal, which could lead to more personalized treatment approaches.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hydromorphone, naloxone, lofexidine
What this could lead to: If successful, this could help doctors better predict and manage withdrawal symptoms, making detox more comfortable and personalized.
What could go wrong: This is a small, early-phase study focused on measuring symptoms, not testing a new treatment. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID CRAVING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence substance withdrawal syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID CRAVING OPIOID WITHDRAWAL OPIOID-USE DISORDER

Contacts and locations

Locations

University of Maryland
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.